CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced the launch of xeo+ in select international markets at the International Master Course on Aging Science (IMCAS) conference in Paris, France, held January 30 – February 1.

Built upon the trusted reputation of Cutera’s original xeo, the xeo+ laser and light-based multi-application aesthetic platform offers versatility and performance to meet the dynamic needs of modern practices.

“We are proud to continue the global legacy of xeo with the launch of xeo+. It marks a significant milestone for Cutera as we continue to lead the charge in innovation,” said Brent Hauser, President of International at Cutera. “xeo+ combines the over 20-year history of xeo, with modern advancements to in-demand treatment applications helping providers achieve effective outcomes for their patients.” Introduced in 2003, xeo pioneered Nd:YAG laser technology and no-downtime treatment protocols as the first 1064 nm laser with contact cooling. Its signature skin revitalization treatment, Laser GenesisTM , is designed for all skin types, utilizing proprietary micro pulses to stimulate the skin in a comfortable 15-minute session. The treatment has become widely popular among thousands of providers and patients worldwide.

Engineered to deliver a more streamlined approach to aesthetics, xeo+ offers faster treatment times, an intuitive user interface, and a host of versatile features for an elevated experience.

The xeo+ platform is optimized with larger spot size options and upgraded contact cooling for comfort, resulting in faster Laser Genesis and hair removal treatments. The technology also includes improved ergonomic laser and IPL handpieces, ranging from the CoolView®, Limelight® , Prowave, and AcutipTM, all designed for enhanced visibility and ease of use.

Sarah Hudson “xeo was one of the first aesthetic platforms I introduced in my practice and has been one of the most dependable technologies I have ever owned. Upgrading to xeo+ was a natural next step. I am truly impressed with the new features, speedier treatment times, and overall efficiency, which has allowed me to offer my patients more.” Addressing the most popular aesthetic concerns, xeo+ offers over 25 solutions encompassing skin revitalization, hair removal, vascular, pigment reduction, and more. The flexibility and customization of applications allow practices the opportunity to widen their patient demographic and keep pace with evolving treatment demands.

Cutera will continue to release xeo+ in additional markets throughout 2025. Interested providers are encouraged to visit www.cutera.com for more information.

About Cutera, Inc.

Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera has strived to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1800 CUTERA or visit cutera.com/au-en/products/xeo-plus/

xeo+ Indications

The CoolView 1064 nm wavelength handpiece is indicated for the removal of unwanted hair, stable long-term, or permanent hair reduction through selective targeting of melanin in hair follicles, treatment of pseudofolliculitis barbae, coagulation and hemostasis of benign vascular lesions such as, but not limited to, hemangiomas, port wine stains, telangiectasias, rosacea, venous lakes, leg veins, spider veins and poikiloderma of Civatte, treatment of wrinkles such as, but not limited to, periocular and perioral wrinkles, reduction of red pigmentation in hypertrophic scars where vascularity is an integral part of the scar, treatment of warts, treatment of mild to moderate inflammatory acne vulgaris. The 1064 nm wavelength is indicated for use on all skin types (Fitzpatrick I-VI), including tanned skin.

The Limelight IPL handpiece is intended for use in surgical, aesthetic, and cosmetic applications requiring selective photothermolysis in the medical specialties of general and plastic surgery, and dermatology.

The Prowave IPL handpiece is indicated for the removal of unwanted hair, and to effect stable, long-term, or permanent, hair reduction.

The Acutip IPL handpiece is intended for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis in the medical specialties of general and plastic surgery, and dermatology.

Xeo+ Important Safety Information

The following treatment-related expected transient side effects and possible adverse events may occur during or following treatment with xeo+: Erythema; Edema; Purpura; Hyperpigmentation; Hypopigmentation; Burns; Erosion; Epidermal crusting; Blistering; Scarring; Deep tissue injury; Prolonged wound healing; Temporary or permanent gray hair; Stimulation of terminal hair growth; Undesired hair loss in hair-bearing areas; Red rash/bumps; Hemosiderin staining; textural changes; Cutaneous indentations; Sun exposure, tanning beds, and artificial tanning may increase the risk of side effects and adverse events. Do not use xeo+ if you are pregnant or are undergoing treatment for skin cancer. Additional contraindications can be discussed during a treatment consultation.

Previous articleDr Alice Rudd to present new findings on polynucleotides for pigmentation